Kidney Res Clin Pract > Volume 42(2); 2023 > Article |
|
CKD, chronic kidney disease; CLL, chronic lymphocytic leukemia; CML, chronic myeloid leukemia; CNI, calcineurin inhibitor; COVID-19, coronavirus disease 2019; Cs, corticosteroid; Csa, cyclosporin A; eGFR, estimated glomerular filtration rate; FSGS, focal segmental glomerulosclerosis; HBP, high blood pressure; HD, hemodialysis; hsCRP, high sensitivity C-reavtive protein; MCD, minimal change disease; MMF, mycophenolate mofetil; MPGN, membranoproliferative glomerulonephritis; NA, not available; NASH, nonalcoholic steatohepatitis; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; Tac, tacrolimus.
Inès Dufour
https://orcid.org/0000-0002-2108-5280
Arnaud Devresse
https://orcid.org/0000-0003-4943-788X
Anais Scohy
https://orcid.org/0000-0003-4644-2077
Caroline Briquet
https://orcid.org/0000-0002-0142-8741
Hélène Georgery
https://orcid.org/0000-0003-3944-0436
Philippe Delaey
https://orcid.org/0000-0002-2950-0303
Julien De Greef
https://orcid.org/0000-0003-0200-1237
Eric Goffin
https://orcid.org/0000-0001-9242-7148
Laura Labriola
https://orcid.org/0000-0003-4133-881X
Skeletal muscle energetics in patients with moderate to advanced kidney disease2022 January;41(1)
The Usefulness of NT-proBNP in Children with Chronic Kidney Disease2009 May;28(3)